Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
AssigneesHumabs Biomed SA, Institut Pasteur
InventorsDavide Corti, Hervé Bourhy
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies, and antigen binding fragments thereof that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
Claims16
An isolated antibody, or an antigen binding fragment thereof, that neutralizes a lyssavirus infection, wherein the antibody, or the antigen binding fragment thereof, comprises heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences as set forth in SEQ ID NOs:
- 165-169 and 171, respectively, or in SEQ ID NOs:
- 165-168 and 170-171, respectively.
Dependencies are inferred from the claim text.